NLS Pharmaceutics (NLSP) Competitors $1.72 -0.01 (-0.58%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.70 -0.01 (-0.87%) As of 05/21/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. ABVC, CLNN, ALXO, NNVC, LSTA, MIRA, IPA, VOR, FNCH, and QTTBShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include ABVC BioPharma (ABVC), Clene (CLNN), ALX Oncology (ALXO), NanoViricides (NNVC), Lisata Therapeutics (LSTA), MIRA Pharmaceuticals (MIRA), ImmunoPrecise Antibodies (IPA), Vor Biopharma (VOR), Finch Therapeutics Group (FNCH), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. ABVC BioPharma Clene ALX Oncology NanoViricides Lisata Therapeutics MIRA Pharmaceuticals ImmunoPrecise Antibodies Vor Biopharma Finch Therapeutics Group Q32 Bio NLS Pharmaceutics (NASDAQ:NLSP) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Which has more risk and volatility, NLSP or ABVC? NLS Pharmaceutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Does the media prefer NLSP or ABVC? In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. NLS Pharmaceutics' average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer NLSP or ABVC? NLS Pharmaceutics received 8 more outperform votes than ABVC BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformNLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% ABVC BioPharmaN/AN/A Do insiders & institutionals hold more shares of NLSP or ABVC? 11.4% of ABVC BioPharma shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 11.9% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher earnings & valuation, NLSP or ABVC? ABVC BioPharma has higher revenue and earnings than NLS Pharmaceutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$12.17MN/AN/AABVC BioPharma$508.38K39.26-$10.52M-$0.13-9.15 Is NLSP or ABVC more profitable? NLS Pharmaceutics has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. NLS Pharmaceutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A ABVC BioPharma -1,619.65%-104.94%-56.81% SummaryNLS Pharmaceutics beats ABVC BioPharma on 5 of the 9 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.19M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / BookN/A6.466.794.50Net Income-$12.17M$143.98M$3.23B$248.18M7 Day Performance6.83%2.03%1.53%0.20%1 Month Performance20.28%4.11%10.06%12.37%1 Year Performance975.67%-2.87%16.72%7.04% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$1.72-0.6%N/A+1,024.2%$6.19MN/A0.006News CoverageABVCABVC BioPharma0.1955 of 5 stars$1.38-6.8%N/A+10.2%$23.15M$508,384.00-1.6030Gap DownCLNNClene2.5288 of 5 stars$2.63+2.3%$40.00+1,420.9%-66.2%$23.09M$350,000.00-0.50100ALXOALX Oncology3.2288 of 5 stars$0.43-1.4%$3.54+720.8%-97.0%$23.03MN/A-0.1440Analyst ForecastNNVCNanoViricidesN/A$1.46+3.5%N/A-33.6%$22.84MN/A-2.0320Gap UpLSTALisata Therapeutics2.7947 of 5 stars$2.63flat$15.00+470.3%-16.9%$22.66M$1M-1.0530Gap UpMIRAMIRA Pharmaceuticals2.1384 of 5 stars$1.32-9.0%$14.00+960.6%+18.6%$22.33MN/A-2.362News CoverageIPAImmunoPrecise Antibodies2.2468 of 5 stars$0.49-1.4%$4.00+719.7%-56.7%$22.33M$24.00M-0.6380News CoverageVORVor Biopharma2.7944 of 5 stars$0.18-0.8%$7.06+3,921.2%-89.4%$22.11MN/A-0.11140High Trading VolumeFNCHFinch Therapeutics GroupN/A$13.48+1.7%N/A+486.2%$21.65M$110,000.00-1.53190QTTBQ32 Bio2.12 of 5 stars$1.74-1.7%$24.71+1,320.4%-94.5%$21.59M$-6,651,000.00-0.1239Gap Down Related Companies and Tools Related Companies ABVC BioPharma Alternatives Clene Alternatives ALX Oncology Alternatives NanoViricides Alternatives Lisata Therapeutics Alternatives MIRA Pharmaceuticals Alternatives ImmunoPrecise Antibodies Alternatives Vor Biopharma Alternatives Finch Therapeutics Group Alternatives Q32 Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
